Literature DB >> 20630594

Characteristics of patients receiving vasopressors.

Julie Benbenishty1, Charles Weissman, Charles L Sprung, Mali Brodsky-Israeli, Yoram Weiss.   

Abstract

BACKGROUND: Patients receiving intensive care frequently need pharmacologic support of their blood pressure because of shock. In some patients, shock is so severe that extremely high doses of vasopressors are needed to elevate their blood pressure.
OBJECTIVE: We sought to ascertain the maximal dose of vasopressors administered to patients, and to describe the population of patients receiving vasopressors in one intensive care unit.
METHODS: All adult patients admitted in 2001 to a 10-bed surgical unit in a university hospital, and receiving a vasopressor agent for 1 hour or more, underwent recordings of their demographic data, diagnoses upon admission, Acute Physiological and Chronic Health Evaluation (APACHE) II scores, vasopressors (including type, initial dose, dose increases, and maximal dose), number of days administered, complications, and mortality.
RESULTS: Of 689 patients whose charts were reviewed, 72 received vasopressors. The mean age was 65 ± 21.4 years, and 66% were male. The mean APACHE II scores were 24 ± 6.2. The administration of .5 μg/kg/minute of norepinephrine or epinephrine resulted in 96% sensitivity and a specificity of 76% for the likelihood of mortality. Using Kaplan-Meyer curves, those patients receiving less than .5 μg/kg/minute demonstrated an 80% 6-year survival. All 17 patients receiving more than 3.8 μg/kg/minute of norepinephrine, and all 5 patients receiving more than 9.6 μg/kg/minute of epinephrine, died. The length of time during which patients received less than their maximal dose of vasopressors had no influence on survival (P = .4). The elderly (aged ≥ 75 years) and the young (aged <75 years) had the same intensive care unit survival rates when receiving vasopressors.
CONCLUSION: In this study, little likelihood of intensive care unit survival was evident when patients received more than .5 μg/kg/minute of norepinephrine or epinephrine.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630594     DOI: 10.1016/j.hrtlng.2010.04.007

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  10 in total

1.  Survival after shock requiring high-dose vasopressor therapy.

Authors:  Samuel M Brown; Michael J Lanspa; Jason P Jones; Kathryn G Kuttler; Yao Li; Rick Carlson; Russell R Miller; Eliotte L Hirshberg; Colin K Grissom; Alan H Morris
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

2.  Should the norepinephrine maximal dosage rate be greatly increased in late shock?

Authors:  Christos Stefanou; Lakis Palazis; Areti Loizou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-03-04

3.  Catecholamine dosing and survival in adult intensive care unit patients.

Authors:  Marc Kastrup; Jan Braun; Magnus Kaffarnik; Vera von Dossow-Hanfstingl; Robert Ahlborn; Klaus-D Wernecke; Claudia Spies
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

4.  Prognosis of patients with shock receiving vasopressors.

Authors:  Xue-Zhong Xing; Hai-Jun Wang; Chu-Lin Huang; Quan-Hui Yang; Shi-Ning Qu; Hao Zhang; Hao Wang; Yong Gao; Qing-Ling Xiao; Ke-Lin Sun
Journal:  World J Emerg Med       Date:  2013

Review 5.  Therapeutic strategies for high-dose vasopressor-dependent shock.

Authors:  Estevão Bassi; Marcelo Park; Luciano Cesar Pontes Azevedo
Journal:  Crit Care Res Pract       Date:  2013-09-15

6.  Outcome of patients with septic shock and high-dose vasopressor therapy.

Authors:  Thomas Auchet; Marie-Alix Regnier; Nicolas Girerd; Bruno Levy
Journal:  Ann Intensive Care       Date:  2017-04-20       Impact factor: 6.925

7.  Effect of Very Low-Dose Hydrocortisone on Shock Reversal in Patients With Septic Shock.

Authors:  Robert Sbertoli; Zeyu Hu; Jonathan Henke; Eric Wu; Shrihari Santosh; Stephen Osmon; Edward Charbek; Zafar Jamkhana; Sadashiv Santosh
Journal:  Crit Care Explor       Date:  2020-04-29

8.  Factors associated with outcomes of septic shock patients receiving high dose noradrenaline according to three primary infection sites.

Authors:  Kang-Song Wu; Dan-Yan Gu; Ting-Ting Wang; Bu-Wen Yu; Kong-Han Pan; Jian-Cang Zhou
Journal:  J Int Med Res       Date:  2019-09-17       Impact factor: 1.671

9.  Protocol Compliance Guiding Angiotensin II Use in Post Cardiovascular Surgery Vasoplegia.

Authors:  Caitlin C Ten Lohuis; Sarah C Burke; Cooper J Jannuzzo; Nicholas A Barker; Edward P Chen; Laurence W Busse
Journal:  Crit Care Explor       Date:  2022-05-13

Review 10.  Angiotensin II: a new therapeutic option for vasodilatory shock.

Authors:  Rachel L Bussard; Laurence W Busse
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.